Company News: Novartis

Share this article:
At a meeting this week, Novartis said it plans to submit cancer compounds Tasigna, for initial therapy in patients with chronic myeloid leukemia (CML), and Zometa, for patients with breast cancer, to the FDA by year's end. Novartis could make several other oncology submissions next year, including one for kidney cancer drug Afinitor, pending the outcome of ongoing clinical trials. In results of one trial, unveiled a day before the meeting, Novartis said Tasigna showed improvement over Gleevec among early-stage leukemia patients. Tasigna is already marketed for the minority of CML patients who are resistant to Gleevec, which is set to lose patent protection starting in 2015. "We have a productive and innovative pipeline that holds promise for many patients," said Joe Jimenez, CEO of the Novartis Pharmaceuticals Division.
 

Share this article:

Email Newsletters

More in Business Briefs

Illumina inks deal with J&J, AstraZeneca, Sanofi

The goal is to develop companion diagnostics to match patients with cancer treatments.

Abbott deal highlights inversion inaction

Political furor over the recent spate of tax inversions is having little influence on how the government chooses its partners.

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.